TRVI Quote, Financials, Valuation and Earnings

Merck & Co., Inc. has a net margin of -- compared to Trevi Therapeutics, Inc.'s net margin of 33.68%. Trevi Therapeutics, Inc.'s return on equity of -35.48% beat Merck & Co., Inc.'s return on equity of 39.63%.

Trevi Therapeutics, Inc. has a consensus price target of $21.00, signalling upside risk potential of 55.9%. On the other hand Merck & Co., Inc. has an analysts' consensus of $106.62 which suggests that it could grow by 6.92%. Given that Trevi Therapeutics, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Trevi Therapeutics, Inc. is more attractive than Merck & Co., Inc..

Trevi Therapeutics, Inc. has a beta of 0.825, which suggesting that the stock is 17.501% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.

Trevi Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.25% to investors and pays a quarterly dividend of $0.81 per share. Trevi Therapeutics, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Trevi Therapeutics, Inc. quarterly revenues are --, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Trevi Therapeutics, Inc.'s net income of -$11.8M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Trevi Therapeutics, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 13.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trevi Therapeutics, Inc. is -- versus 3.93x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Trevi Therapeutics, Inc.'s net margin of -255.85%. Trevi Therapeutics, Inc.'s return on equity of -35.48% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Trevi Therapeutics, Inc. has a consensus price target of $21.00, signalling upside risk potential of 55.9%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -29.75%. Given that Trevi Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Trevi Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Trevi Therapeutics, Inc. has a beta of 0.825, which suggesting that the stock is 17.501% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Trevi Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Trevi Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Trevi Therapeutics, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Trevi Therapeutics, Inc.'s net income of -$11.8M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Trevi Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 2.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trevi Therapeutics, Inc. is -- versus 2.35x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Trevi Therapeutics, Inc.'s net margin of --. Trevi Therapeutics, Inc.'s return on equity of -35.48% beat Palatin Technologies's return on equity of --.

Trevi Therapeutics, Inc. has a consensus price target of $21.00, signalling upside risk potential of 55.9%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Trevi Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than Trevi Therapeutics, Inc..

Trevi Therapeutics, Inc. has a beta of 0.825, which suggesting that the stock is 17.501% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Trevi Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trevi Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Trevi Therapeutics, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Trevi Therapeutics, Inc.'s net income of -$11.8M is higher than Palatin Technologies's net income of --. Notably, Trevi Therapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trevi Therapeutics, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -- compared to Trevi Therapeutics, Inc.'s net margin of --. Trevi Therapeutics, Inc.'s return on equity of -35.48% beat Theriva Biologics, Inc.'s return on equity of -171.04%.

Trevi Therapeutics, Inc. has a consensus price target of $21.00, signalling upside risk potential of 55.9%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3004.21%. Given that Theriva Biologics, Inc. has higher upside potential than Trevi Therapeutics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Trevi Therapeutics, Inc..

Trevi Therapeutics, Inc. has a beta of 0.825, which suggesting that the stock is 17.501% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.

Trevi Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trevi Therapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

Trevi Therapeutics, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Trevi Therapeutics, Inc.'s net income of -$11.8M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Trevi Therapeutics, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trevi Therapeutics, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.